07:05 AM EST, 11/07/2025 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows:

We lift our 12-month target price to $101 from $80, reflecting higher confidence in IPGP's margin recovery and mix shift toward medical, defense, and micromachining applications. Our target implies 52x 2026 EPS of $1.94, above the five-year average, which we believe is warranted by improving gross margins, a debt-free balance sheet, and a growing contribution from higher-value products now exceeding half of revenue. We also raise our 2025 EPS estimate to $1.26 from $1.06 on better cost absorption and mix improvement. However, we maintain our Hold rating as tariff pressures, elevated operating expenses, and still-uneven demand in core materials processing limit near-term earnings power and leave limited upside to our revised valuation. In our view, shares fairly balance transformation potential with execution and macroeconomic risks.